US FDA approves AstraZeneca & Daiichi Sankyo’s Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer ...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 …